Key statistics
As of last trade, BioMarin Pharmaceutical Inc (0HNC:LSE) traded at 59.99, 19.69% above the 52 week low of 50.12 set on Dec 19, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 59.99 |
| Low | 59.99 |
| Bid | -- |
| Offer | -- |
| Previous close | 60.07 |
| Average volume | 2.64k |
|---|---|
| Shares outstanding | 192.11m |
| Free float | 190.68m |
| P/E (TTM) | 22.36 |
| Market cap | 11.46bn USD |
| EPS (TTM) | 2.67 USD |
Data delayed at least 20 minutes, as of Feb 11 2026 16:07 GMT.
More ▼
Press releases
- BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
- BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer
- BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
- Veeva and BioMarin Form Long-Term Strategic Partnership
- Veeva and BioMarin Form Long-Term Strategic Partnership
- BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
More ▼
